These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 32336178)

  • 1. Parkinson's disease and osteoporosis: basic and clinical implications.
    Figueroa CA; Rosen CJ
    Expert Rev Endocrinol Metab; 2020 May; 15(3):185-193. PubMed ID: 32336178
    [No Abstract]   [Full Text] [Related]  

  • 2. Parkinson's disease and osteoporosis.
    van den Bos F; Speelman AD; Samson M; Munneke M; Bloem BR; Verhaar HJ
    Age Ageing; 2013 Mar; 42(2):156-62. PubMed ID: 23132148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteoporosis: A Hidden Nonmotor Face of Parkinson's Disease.
    Metta V; Sanchez TC; Padmakumar C
    Int Rev Neurobiol; 2017; 134():877-890. PubMed ID: 28805587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. α-Synuclein and Lewy pathology in Parkinson's disease.
    Kalia LV; Kalia SK
    Curr Opin Neurol; 2015 Aug; 28(4):375-81. PubMed ID: 26110807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?
    Schulz-Schaeffer WJ
    Biomolecules; 2015 Jul; 5(3):1467-79. PubMed ID: 26193328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Membrane lipids as therapeutic targets for Parkinson's disease: a possible link between Lewy pathology and membrane lipids.
    Kubo SI
    Expert Opin Ther Targets; 2016 Nov; 20(11):1301-1310. PubMed ID: 26610255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting alpha-synuclein for the treatment of Parkinson's disease.
    Rohn TT
    CNS Neurol Disord Drug Targets; 2012 Mar; 11(2):174-9. PubMed ID: 22483285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pathomechanisms underlying Parkinson's disease.
    Jellinger KA
    Expert Rev Neurother; 2014 Feb; 14(2):199-215. PubMed ID: 24471711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts.
    Jellinger KA
    Mov Disord; 2012 Jan; 27(1):8-30. PubMed ID: 22081500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathological biochemistry of alpha-synucleinopathy.
    Iwatsubo T
    Neuropathology; 2007 Oct; 27(5):474-8. PubMed ID: 18018483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parkinson's disease from the gut.
    Liddle RA
    Brain Res; 2018 Aug; 1693(Pt B):201-206. PubMed ID: 29360467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
    Lee VM; Trojanowski JQ
    Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parkinson's disease: A risk factor for osteoporosis.
    Malochet-Guinamand S; Durif F; Thomas T
    Joint Bone Spine; 2015 Dec; 82(6):406-10. PubMed ID: 26453100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. α-Synuclein pathology in Parkinson's disease and related α-synucleinopathies.
    Henderson MX; Trojanowski JQ; Lee VM
    Neurosci Lett; 2019 Sep; 709():134316. PubMed ID: 31170426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?
    Volpicelli-Daley LA; Kirik D; Stoyka LE; Standaert DG; Harms AS
    J Neurochem; 2016 Oct; 139 Suppl 1(Suppl 1):131-155. PubMed ID: 27018978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates.
    Wakabayashi K; Tanji K; Mori F; Takahashi H
    Neuropathology; 2007 Oct; 27(5):494-506. PubMed ID: 18018486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TIGAR inclusion pathology is specific for Lewy body diseases.
    López KLR; Simpson JE; Watson LC; Mortiboys H; Hautbergue GM; Bandmann O; Highley JR
    Brain Res; 2019 Mar; 1706():218-223. PubMed ID: 30267647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Lewy body formation in Parkinson's disease: neurodegeneration or neuroprotection?].
    Wakabayashi K
    Rinsho Shinkeigaku; 2008 Nov; 48(11):981-3. PubMed ID: 19198138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical and pathological study on early diagnosis of Parkinson's disease and dementia with Lewy bodies].
    Orimo S
    Rinsho Shinkeigaku; 2008 Jan; 48(1):11-24. PubMed ID: 18386627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.